

Special Issue

Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma

Message from the Guest Editors

Head and neck squamous cell carcinoma (HNSCC) remains a major clinical challenge due to its high heterogeneity, frequent late-stage diagnosis, and resistance to conventional therapies. Central to its pathogenesis is the tumor microenvironment (TME), which is a complex and dynamic network composed of cancer cells, stromal cells, immune infiltrates, extracellular matrix components, and signaling molecules. This environment plays a crucial role in modulating tumor growth, invasion, immune escape, and therapy resistance. Understanding the cellular and molecular interactions within the TME, including the roles of cancer-associated fibroblasts (CAFs), immune checkpoints, and tumor-infiltrating lymphocytes (TILs), is essential for advancing precision medicine in HNSCC. The current Special Issue invites contributions focused on the molecular and cellular components of the TME in HNSCC, aiming to uncover novel insights for improved prognosis and therapeutic innovation.

- Keywords

- head and neck oncology 3D tumor models
- cancer-associated fibroblasts
- phototherapy
- exosomes

Guest Editors

Dr. Julia Federspiel

Dr. Teresa Steinbichler

Dr. Jozsef Dudas

Deadline for manuscript submissions

31 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/246101

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).